NANOBIOTIX to Participate in Jefferies London Healthcare Conference
NANOBIOTIX (NASDAQ: NBTX) said company management will participate in a fireside chat at the Jefferies London Healthcare Conference on Monday, November 17, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NANOBIOTIX (NASDAQ: NBTX) said company management will participate in a fireside chat at the Jefferies London Healthcare Conference on Monday, November 17, 2025. The session is scheduled for 3:00 PM GMT / 10:00 AM ET / 4:00 PM CET in London.
Presenters listed are Laurent Levy, Chief Executive Officer, and Bart van Rhijn, Chief Financial & Business Officer. The fireside chat will be webcast live from the company’s investors events page, with a replay available after the event.
Details
News Market Reaction – NBTX
On Nov 12, the first trading day after this news, NBTX closed 3.13% above the previous close.
Data tracked by StockTitan Argus for the Nov 12 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference:
Jefferies London Healthcare Conference
Date: Monday, November 17, 2025
Time: 3pm GMT / 10am ET / 4pm CET
Location: London, UK
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. Replay of the webcast will be available following the event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2025-11-10 -- NBTX -- Presenting @ Jefferies -- FINAL
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.